The rationale for B lymphocyte depletion in Graves' disease.: Monoclonal anti-CD20 antibody therapy as a novel treatment option

被引:57
|
作者
El Fassi, Daniel [1 ]
Nielsen, Claus H.
Hasselbalch, Hans C.
Hegedus, Laszlo
机构
[1] Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense C, Denmark
[2] Odense Univ Hosp, Dept Hematol, DK-5000 Odense C, Denmark
[3] Natl Univ Hosp, Rigshosp, Inst Inflammat Res, Copenhagen, Denmark
关键词
D O I
10.1530/eje.1.02140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have reviewed the immunology of thyroid autoimmunity with special reference to the importance of B lymphocytes (B cells) in thyroidal and extrathyroidal Graves' disease (GD), thus providing a framework for the hypothesis that B cell depletion may be beneficial in GD. Additionally, after reviewing the efficacy and safety in other autoimmune diseases, we propose that treatment with the B cell-depleting agent Rituximab may become a clinically relevant treatment option in selected cases of GD, particularly when complicated with thyroid-associated ophthalmopathy.
引用
收藏
页码:623 / 632
页数:10
相关论文
共 50 条
  • [1] Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab:: an open study
    Salvi, Mario
    Vannucchi, Guia
    Campi, Irene
    Curro, Nicola
    Dazzi, Davide
    Simonetta, Simona
    Bonara, Paola
    Rossi, Stefania
    Sina, Clara
    Guastella, Claudio
    Ratiglia, Roberto
    Beck-Peccoz, Paolo
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 156 (01) : 33 - 40
  • [2] Ofatumumab: a novel monoclonal anti-CD20 antibody
    Lin, Thomas S.
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
  • [3] B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism
    Ueki, I.
    Abiru, N.
    Kobayashi, M.
    Nakahara, M.
    Ichikawa, T.
    Eguchi, K.
    Nagayama, Y.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 163 (03): : 309 - 317
  • [4] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3525 - 3530
  • [5] Novel anti-CD20 monoclonal antibody shows promise as therapy for RA
    [J]. Nature Clinical Practice Rheumatology, 2008, 4 (12): : 623 - 623
  • [6] Anti-CD20 monoclonal antibody therapy in multiple myeloma
    Kapoor, Prashant
    Greipp, Patricia T.
    Morice, William G.
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    Greipp, Philip R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 135 - 148
  • [7] Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy
    Decaudin, D
    Des Guetz, G
    Mathiot, C
    Dumont, J
    Hubert, P
    Vincent-Salomon, A
    Pouillart, P
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (01) : 171 - 172
  • [8] Anti-CD20 monoclonal antibody treatment in six patients with chronic graft-versus-host disease.
    Canninga-van Dijk, MR
    van der Straaten, HM
    Fijnheer, R
    van den Tweel, JG
    Verdonck, LF
    [J]. BLOOD, 2003, 102 (11) : 720A - 720A
  • [9] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [10] Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
    Chuda, Ravindra R.
    Vishnu, Prakash
    Aboulafia, David
    [J]. CURRENT DRUG THERAPY, 2012, 7 (04) : 281 - 289